Opportunities Preloader

Please Wait.....

Report

Global Atrial Fibrillation Market - Treatment Types and End-User Facilities

Market report I 2022-05-02 I 246 Pages I Industry Experts

Report Synopsis

Atrial Fibrillation (AF) is the most common arrhythmia, which can lead to stroke, peripheral embolization, heart failure and other unfavorable outcomes. While the incidence of AF among the general population has been found to be at about 2.3%-3.4%, this registers a significant increase in patients with pulmonary disease, critical illness or systemic inflammatory response syndrome, with devastating clinical impact. A number of recent epidemiological studies have established a greater risk of AF and new-onset AF among patients with COVID-19, though the results have been quite inconsistent. The literature available thus far has indicated that AF or new-onset AF can have a substantial association with the worst outcomes, viz., mortality, in patients with COVID-19.

Apart from the recent development of COVID-19 and its effect on AF, other factors that increase the risk of this condition include growing worldwide prevalence of obesity and heart diseases. The rise in the number of AF cases is fueling the market for treating this disease, though at the same time posing a crushing burden on the economies of several countries because of the high treatment cost involved.

Research Findings & Coverage
- Global Atrial Fibrillation market is analyzed in this report with respect to treatment type/sub-type, end-user facilities
- The study exclusively analyzes the market size of each treatment type/sub-type and end-user facility of Atrial Fibrillation by all major geographic regions/countries
- Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrythmias
- Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF)
- Thumb ECGs Playing a Greater Role Atrial Fibrillation Detection
- Revolutionary Catheter Ablation Technologies for AF Take Centerstage
- Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
- Major companies profiled - 19
- The industry guide includes the contact details for 70 companies

Product Outline
The report analyzes the market for the following key treatment types/sub-types of Atrial Fibrillation:
- Non-Pharmacological Treatment
o Catheter Ablation
o Electric Cardioversion
o High Intensity Focused Ultrasound (HIFU)
o Maze Surgery
o Other Ablation Treatments
- Pharmacological Treatment
o Blood Thinners
o Heart Rate Drugs
o Heart Rhythm Drugs

End-User Facilities of Atrial Fibrillation analyzed in this study comprise the following:
- Ambulatory Surgical Centers
- Cardiac Centers
- Hospitals

Analysis Period, Units and Growth Rates
- The report reviews, analyzes and projects the global Atrial Fibrillation market for the period 2018-2027 in terms of market value in US$ and the compound annual growth rates (CAGRs) projected from 2022 through 2027 with a special focus on y-o-y growth for 2019, 2020 and 2021

Geographic Coverage
- North America (The United States, Canada and Mexico)
- Europe (France, Germany, Italy, the United Kingdom and Rest of Europe)
- Asia-Pacific (China, India, Japan and Rest of Asia-Pacific)
- Rest of World

TABLE OF CONTENTS

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION
1.1 Product Outline
1.1.1 An Overview of Atrial Fibrillation
1.1.1.1 Classification of AF
1.1.1.1.1 Paroxysmal (Self-Terminating or Intermittent) Atrial Fibrillation
1.1.1.1.2 Persistent Atrial Fibrillation
1.1.1.1.3 Permanent Atrial Fibrillation
1.1.1.1.4 Lone Atrial Fibrillation
1.1.1.2 Clinical Features
1.1.1.3 Risk factors for Atrial Fibrillation
1.1.1.3.1 Clinical Risk Factors
1.1.1.3.2 Reversible Risk Factors
1.1.1.3.3 Nonmodifiable Factors
1.1.1.3.4 Emerging Risk Factors
1.1.2 Treatment of Atrial Fibrillation (AF)
1.1.2.1 Non-Pharmacological Treatments
1.1.2.1.1 Catheter Ablation
1.1.2.1.2 Electric Cardioversion
1.1.2.1.3 High Intensity Focused Ultrasound (HIFU)
1.1.2.1.4 Maze Surgery
1.1.2.1.5 Other Ablation Treatments
1.1.2.1.5.1 Cryoablation
1.1.2.1.5.2 Microwave Ablation
1.1.2.1.5.3 Radiofrequency Ablation
1.1.2.2 Pharmacological Treatments
1.1.2.2.1 Blood Thinners
1.1.2.2.1.1 Antiplatelet Drugs
1.1.2.2.1.2 Anticoagulants Drugs
1.1.2.2.2 Heart Rate Drugs
1.1.2.2.2.1 Beta-Blockers
1.1.2.2.2.2 Calcium Channel Blockers
1.1.2.2.2.3 Digitalis Glycosides
1.1.2.2.3 Heart Rhythm Drugs
1.1.2.2.3.1 Sodium Channel Blockers
1.1.2.2.3.2 Potassium Channel Blockers

2. AF TREATMENT BY END-USER FACILITIES - MARKET SNAPSHOT
2.1 Ambulatory Surgical Centers
2.2 Cardiac Centers
2.3 Hospitals

3. KEY MARKET TRENDS
3.1 Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrythmias
3.2 Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF)
3.3 Thumb ECGs Playing a Greater Role Atrial Fibrillation Detection
3.4 Atrial Fibrillation Treated Successfully through Pulsed Field Ablation
3.5 Revolutionary Catheter Ablation Technologies for AF Take Centerstage

4. KEY GLOBAL PLAYERS
Abbott Laboratories (United States)
Atricure, Inc. (United States)
Biosense Webster, Inc. (United States)
Biotronik SE & Co. Kg (Germany)
Boehringer Ingelheim International GmbH (Germany)
Boston Scientific Corporation (United States)
Bristol-Myers Squibb Co. (United States)
Cardiofocus, Inc. (United States)
Cathrx Ltd (Australia)
Medtronic Plc (Ireland)
Osypka AG (Germany)
Pfizer Inc. (United States)
Shanghai Microport Medical (Group) Co Ltd (China)
Siemens Medical Solutions USA, Inc. (United States)

5. KEY BUSINESS & PRODUCT TRENDS
Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX LAAC Device
Boston Scientific Closes Acquisition of Baylis Medical Company Inc.
Medtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition
Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms
Acutus Medical's Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium
Medtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System
Medtronic to Acquire Affera
Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation
Continuous Rhythm Monitoring Reveals Strong Short-Term Risk Association Between Atrial Fibrilation Episodes and Ischemic Stroke
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
Biosense Webster Announces Completion of Atrial Fibrillation Cases Using Novel HELIOSTAR Balloon Ablation Catheter
New Data & Innovations: Heart Rhythm 2021
BIOTRONIK Expands Range of Peripheral Introducer Sheaths
CardioFocus-Announces-Agreement-to-Acquire-Intellectual-Property-Press-Release.pdf
Late-Breaking Data Shows Abbott's Amplatzer Amulet Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman Device for People With Atrial Fibrillation at Risk of Stroke
Abbott's Amplatzer Amulet Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
AcQMap 8, Acutus Medical's Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark
Real-World Data Demonstrate Significant Reduction in Complications and Reinterventions with Medtronic Micra Leadless Pacemaker
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
Abbott Receives European And Canadian Approval For Amplatzer Steerable Delivery Sheath To Optimize Left Atrial Appendage Closure Procedures For People At Risk Of Stroke
Medtronic Receives FDA Expanded Approval for Arctic Front Family of Cardiac Cryoablation Catheters for Initial Use for Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Abbott Introduces Jot Dx Insertable Cardiac Monitor, Designed To Reduce Data Burden And Improve Accurate Diagnosis Of Difficult-To-Detect Abnormal Heart Rhythms
AliveCor and Acutus Medical Partner to Evaluate Management and Treatment of Cardiac Arrhythmias
New Data & Innovations: Heart Rhythm 2021
BIOTRONIK's Cardiac Monitor Receives Prestigious Award
Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX Left Atrial Appendage Closure Device
CardioFocus to Exhibit and Present Data Supporting HeartLight X3 System at Heart Rhythm 2021
CardioFocus Receives Regulatory Approval to Market HeartLight X3 System in Japan
Medtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring
CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China
GE Healthcare and the American College of Cardiology Join Forces to Advance AI in Cardiac Care
Medtronic Launches App-Based Study to Better Understand Relationship Between Atrial Fibrillation Disease Burden and Impact on Patient Outcomes
Siemens Healthineers Receives CE Mark for the ACUSON AcuNav Volume ICE Catheter
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate FORCE Sensing Ablation System
Japan Lifeline Finalizes Supply Agreement for Pulsed Electric Field Ablation Catheter for U.S. Market
Acutus Medical Announces FDA Clearance of AcQCross, a Full Suite of Universal Transseptal Crossing Devices
Acutus Medical Initiates First IDE Therapy Trial with the AcQBlate FORCE Sensing Ablation System
AtriCure's EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
Acutus Medical Receives Vizient Innovative Technology Contract
Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation
CardioFocus Announces Expanded Partnership With Japan Lifeline
CardioFocus Announces Expanded Distribution Partnership With MicroPort CRM To Include Spain And Portugal
Medtronic Receives FDA Approval of DiamondTemp Ablation System for the Treatment of Patients with Atrial Fibrillation
Acutus Medical Announces CE Mark and European Launch of AcQCross Transseptal System, a Fully Integrated Family of Transseptal Crossing Products
CardioFocus Announces 10,000 Patients Treated Worldwide
First Clinical Implantation of MicroPort Left
Abbott Introduces Next-Generation 3d Cardiac Mapping Platform In Europe And Australia
The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy
Acutus Medical Launches AcQBlate Force Sensing Ablation System in Europe
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
Acutus Medical Announces FDA Clearance of Second-Generation AcQMap 3D Imaging & Mapping Catheter
Acutus Medical Announces Pulsed Field Ablation Program and Initial Pre-Clinical Results
Medtronic Gains FDA Clearance, CE Mark for LINQ II Insertable Cardiac Monitor (ICM)
Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic Support
Medtronic Micra AV Receives CE Mark
New Alliance Maps the Way in Electrophysiology
CardioFocus Announces US FDA Approval of HeartLight X3 System for the Treatment of Atrial Fibrillation
GE Healthcare and Preventice Solutions Collaborate to Connect the Heart, the Hospital and the Home Seamlessly
Bristol Myers Squibb - The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis

6. GLOBAL MARKET OVERVIEW
6.1 Global Atrial Fibrillation Market Overview by Treatment Type
6.1.1 Global Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
6.1.2 Global Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
6.1.3 Atrial Fibrillation Treatment Type Market Overview by Global Region
6.1.3.1 Non-Pharmacological
6.1.3.1.1 Atrial Fibrillation's Non-Pharmacological Treatment Sub-Type Market Overview by Global Region
6.1.3.1.1.1 Catheter Ablation
6.1.3.1.1.2 Electric Cardioversion
6.1.3.1.1.3 High Intensity Focused Ultrasound (HIFU)
6.1.3.1.1.4 Maze Surgery
6.1.3.1.1.5 Other Ablation Treatments
6.1.3.2 Pharmacological
6.1.3.2.1 Atrial Fibrillation's Pharmacological Treatment Sub-Type Market Overview by Global Region
6.1.3.2.1.1 Blood Thinners
6.1.3.2.1.2 Heart Rate Drugs
6.1.3.2.1.3 Heart Rhythm Drugs
6.2 Global Atrial Fibrillation Market Overview by End-User Facility
6.2.1 Atrial Fibrillation End-User Facility Market Overview by Global Region
6.2.1.1 Ambulatory Surgical Centers
6.2.1.2 Cardiac Centers
6.2.1.3 Hospitals

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

7. NORTH AMERICA
7.1 North American Atrial Fibrillation Market Overview by Geographic Region
7.2 North American Atrial Fibrillation Market Overview by Treatment Type
7.2.1 North American Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
7.2.2 North American Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
7.3 North American Atrial Fibrillation Market Overview by End-User Facility
7.4 Major Market Players
Abbott Laboratories (United States)
Acutus Medical, Inc. (United States)
Atricure, Inc. (United States)
Biosense Webster, Inc. (United States)
Boston Scientific Corporation (United States)
Bristol-Myers Squibb Co. (United States)
Cardiofocus, Inc. (United States)
GE Healthcare (United States)
Pfizer Inc. (United States)
Siemens Medical Solutions USA, Inc. (United States)

7.5 Country-wise Analysis of North American Atrial Fibrillation Market
7.5.1 The United States
7.5.1.1 United States' Atrial Fibrillation Market Overview by Treatment Type
7.5.1.1.1 United States' Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
7.5.1.1.2 United States' Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
7.5.1.2 United States' Atrial Fibrillation Market Overview by End-User Facility

7.5.2 Canada
7.5.2.1 Canadian Atrial Fibrillation Market Overview by Treatment Type
7.5.2.1.1 Canadian Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
7.5.2.1.2 Canadian Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
7.5.2.2 Canadian Atrial Fibrillation Market Overview by End-User Facility

7.5.3 Mexico
7.5.3.1 Mexican Atrial Fibrillation Market Overview by Treatment Type
7.5.3.1.1 Mexican Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
7.5.3.1.2 Mexican Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
7.5.3.2 Mexican Atrial Fibrillation Market Overview by End-User Facility

8. EUROPE
8.1 European Atrial Fibrillation Market Overview by Geographic Region
8.2 European Atrial Fibrillation Market Overview by Treatment Type
8.2.1 European Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
8.2.2 European Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
8.3 European Atrial Fibrillation Market Overview by End-User Facility
8.4 Major Market Players
Acesion Pharma (Denmark)
Afreeze GmbH (Austria)
Biotronik SE & Co. Kg (Germany)
Boehringer Ingelheim International GmbH (Germany)
Medtronic PLC (Ireland)
Osypka AG (Germany)

8.5 Country-wise Analysis of European Atrial Fibrillation Market
8.5.1 France
8.5.1.1 French Atrial Fibrillation Market Overview by Treatment Type
8.5.1.1.1 French Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
8.5.1.1.2 French Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
8.5.1.2 French Atrial Fibrillation Market Overview by End-User Facility

8.5.2 Germany
8.5.2.1 German Atrial Fibrillation Market Overview by Treatment Type
8.5.2.1.1 German Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
8.5.2.1.2 German Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
8.5.2.2 German Atrial Fibrillation Market Overview by End-User Facility

8.5.3 Italy
8.5.3.1 Italian Atrial Fibrillation Market Overview by Treatment Type
8.5.3.1.1 Italian Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
8.5.3.1.2 Italian Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
8.5.3.2 Italian Atrial Fibrillation Market Overview by End-User Facility

8.5.4 The United Kingdom
8.5.4.1 United Kingdom Atrial Fibrillation Market Overview by Treatment Type
8.5.4.1.1 United Kingdom Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
8.5.4.1.2 United Kingdom Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
8.5.4.2 United Kingdom Atrial Fibrillation Market Overview by End-User Facility

8.5.5 Rest of Europe
8.5.5.1 Rest of Europe Atrial Fibrillation Market Overview by Treatment Type
8.5.5.1.1 Rest of Europe Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
8.5.5.1.2 Rest of Europe Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
8.5.5.2 Rest of Europe Atrial Fibrillation Market Overview by End-User Facility

9. ASIA-PACIFIC
9.1 Asia-Pacific Atrial Fibrillation Market Overview by Geographic Region
9.2 Asia-Pacific Atrial Fibrillation Market Overview by Treatment Type
9.2.1 Asia-Pacific Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
9.2.2 Asia-Pacific Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
9.3 Asia-Pacific Atrial Fibrillation Market Overview by End-User Facility
9.4 Major Market Players
Cathrx Ltd (Australia)
Japan Lifeline Co. (Japan)
Shanghai Microport Medical (Group) Co Ltd (China)

9.5 Country-wise Analysis of Asia-Pacific Atrial Fibrillation Market
9.5.1 China
9.5.1.1 Chinese Atrial Fibrillation Market Overview by Treatment Type
9.5.1.1.1 Chinese Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
9.5.1.1.2 Chinese Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
9.5.1.2 Chinese Atrial Fibrillation Market Overview by End-User Facility

9.5.2 India
9.5.2.1 Indian Atrial Fibrillation Market Overview by Treatment Type
9.5.2.1.1 Indian Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
9.5.2.1.2 Indian Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
9.5.2.2 Indian Atrial Fibrillation Market Overview by End-User Facility

9.5.3 Japan
9.5.3.1 Japanese Atrial Fibrillation Market Overview by Treatment Type
9.5.3.1.1 Japanese Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
9.5.3.1.2 Japanese Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
9.5.3.2 Japanese Atrial Fibrillation Market Overview by End-User Facility

9.5.4 Rest of Asia-Pacific
9.5.4.1 Rest of Asia-Pacific Atrial Fibrillation Market Overview by Treatment Type
9.5.4.1.1 Rest of Asia-Pacific Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
9.5.4.1.2 Rest of Asia-Pacific Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
9.5.4.2 Rest of Asia-Pacific Atrial Fibrillation Market Overview by End-User Facility

10. REST OF WORLD
10.1 Rest of World Atrial Fibrillation Market Overview by Treatment Type
10.1.1 Rest of World Atrial Fibrillation Non-Pharmacological Treatment Market Overview by Sub-Type
10.1.2 Rest of World Atrial Fibrillation Pharmacological Treatment Market Overview by Sub-Type
10.2 Rest of World Atrial Fibrillation Market Overview by End-User Facility

PART C: GUIDE TO THE INDUSTRY
NORTH AMERICA
EUROPE
ASIA-PACIFIC
REST OF WORLD

PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE